-+ 0.00%
-+ 0.00%
-+ 0.00%

GENMAB - PETOSEMTAMAB PLUS PEMBROLIZUMAB WELL TOLERATED WITH NO NEW SAFETY SIGNALS IDENTIFIED

Reuters·10/28/2026 13:42:05